TY - JOUR 
A1 - García Lunar, Inés
AU - Blanco Vich, Isabel
AU - Fernández Friera, Leticia
AU - Prat González, Susanna
AU - Jordà, Paloma
AU - Sánchez González, Javier
AU - Pereda, Daniel
AU - Pujadas, Sandra
AU - Rivas Lasarte, Mercedes
AU - García Álvarez, Ana
AU - Et al.
T1 - Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial
Y1 - 2020
SN - 2452-302X
UR - http://hdl.handle.net/11268/8917
AB - Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF].
KW - Hipertensión pulmonar
KW - Tratamiento médico
KW - Aparato respiratorio
KW - Enfermedad
KW - Tratamiento médico
LA - eng
ER -